레오나바이오LONA 주가

Piper Sandler Initiates Coverage On LeonaBio with Overweight Rating, Announces Price Target of $20

Piper Sandler analyst Kelsey Goodwin initiates coverage on LeonaBio (NASDAQ:LONA) with a Overweight rating and announces Price Target of $20.

[SCHEDULE 13G] SCHEDULE 13G

[ARS] ARS — ARS

[DEF 14A] 주주총회 위임장 — DEF 14A

[DEFA14A] DEFA14A — DEFA14A

LeonaBio (NASDAQ:LONA) Beats Q1 Loss Estimates as Phase 3 Breast Cancer Trial Enrollment Expands

LeonaBio Q1 net loss of $1.73/share beats estimates as Phase 3 breast cancer trial progresses. Cash burn rises, stock dips 1.1% in after-hours trading.

LeonaBio Q1 EPS $(1.73) Beats $(2.50) Estimate

LeonaBio (NASDAQ:LONA) reported quarterly losses of $(1.73) per share which beat the analyst consensus estimate of $(2.50) by 30.8 percent. This is a 26.07 percent increase over losses of $(2.34) per share from the same

LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update

Advancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations ...

♻️ 재탕[4] 내부자 거래

[3] 3